Acquisition Opportunity EpiphanyRx was acquired by Navitus in 2021 and rebranding to Navitus in 2025, indicating a transition period where cross-sell of bundled PBM services and specialty drug management solutions to Navitus client base and legacy EpiphanyRx accounts could be viable.

Small Employer Focus The company targets employers with 5,000 lives or fewer, suggesting a revenue opportunity to upsell or expand within small-to-mid market segments currently served by similar PBM providers.

Bundled Solution As Navitus’ in-house fully bundled solution for small groups, there is potential to position expanded savings, hands-on service, and integrated support to existing Navitus customers seeking a consolidated PBM and pharmacy management offering.

Growth by Expansion With a revenue range of 1M to 10M and a parent company footprint, there is room to target mid-size growth accounts, cross-sell to ArchimedesRx specialty drug management capabilities, and leverage Navitus’ broader platform.

Tech & Analytics Leverage Strong digital footprint and analytics stack (HubSpot, Adobe, Azure, WordPress) can be leveraged for targeted marketing, deeper data-driven outreach, and ROI-focused sales campaigns to health-plan and employer groups.